Evidence map›Paper›PMID 36068092›Full record

ArticleAnais brasileiros de dermatologia

Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series.

Matteo Megna, Gabriella Fabbrocini, Lucia Gallo, Angelo Ruggiero, Elisa Camela, Sonia Sofía Ocampo-Garza, Eleonora Cinelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matteo MegnaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy. Electronic address: mat24@libero.it.
Gabriella FabbrociniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy.
Lucia GalloSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy.
Angelo RuggieroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy.
Elisa CamelaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy.
Sonia Sofía Ocampo-GarzaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy; Universidad Autónoma de Nuevo León, Hospital Universitario "Dr. José Eleuterio González", Departamento de Dermatología, Monterrey, Nuevo León, México.
Eleonora CinelliSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PsoriasisTumor Necrosis Factor InhibitorsAdalimumabChildEtanerceptHumansInfliximabTumor Necrosis Factor-alphaAdalimumabEtanerceptInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Identifiers

PMID36068092
PMCPMC9582888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.